Connect with us

Cannabis News

Cannabis Seed Oil Has ‘Superior Effectiveness’ In Healing Wounds Compared To Conventional Antibiotics, Study Shows

Published

on

Cannabis seed oils can help accelerate the healing of skin wounds. The authors say that “HEMP seed oil can help with wound management and cost effective”.

Report, published in the journal Narra J, compared hypsea oils against oil against treats treated with conventional antibiotics chlorampenicol. Another group of mice only gave salt solution.

“The findings of the study of the healing processes of the wounds, especially the processes of healing wounds, epithelialization, granulation tissue formation and vascularization.

The four-person research team of Indonesia Universitas Syiah, has not been taken into account that the treatment of Hamp oil has exceeded the treatment of the healing process that surpassed treatment with chlorampenicol. The other season, however, seemed to be “comparable to antibiotic.

“Kalametro seed oil showed the effectiveness of the rapid sized size,” the paper said. In terms of epithelialization, the significant effects of the two treatments, the seed oils in today’s research can provide special benefits in this critical phase of wound healing, potentially accelerating a hundred retraining transition. “

In terms of fabric formation, the treatment of the HEMP Seed was significantly accelerated in the formation of the formation of granulation, especially in 14 days, where he wrote “.” However, the effect of 21 days was comparable with chlorampenicol “.

“Hemp seed oil showed great potential to speed healing processes, especially the reduction of wound size, epithelialization, granulation tissue formation and vascularization.

“According to the day, the treatment of hemp seed oil is more pronounced with chlorampenicol and control groups compared to chlorampenicol and control groups, even if the fibers were somewhat disorganized,” reports follow. “Depending on the day, according to the year, the granulation fabric in the treatment of hemp seed oil indicates the most advanced and well-organized structure, compared to chloramphenicol and control groups.”

The results showed HEMP Seed oil treatment “21 days of vascularization has increased significantly, no effect 3, 7, or 14 days”

“Day 21, vascularization, chalmu-seed oil treatment, chlorophenicol and negative control groups, basascularization, forming new blood vessels …” The critical role of the healing of the wounds is the new formation of the blood vessel. “

As for the mechanisms working in the treatment of cannabis, the authors were “combined activities” of multiple compounds.

“HEMP seed oil has different bioactive ingredients, each has the potential to accelerate the specific phases of the wound healing”, they write:

“Polyminstrated fatty acids, regulating the inflammatory phase, which reduce the inflammatory phase. Terpenoids and flavonoids, which reduce oxidizing stress, cannabinoids. Cannapidiols shows inflammatory and antimicrobial effects, essential for infection control and balanced immune responses. “

“The combined actions of these compounds proposed that HEMP seed oil can improve wounds in many ways,” exam says “effectively addressing the inflammatory and abundance stages.”

Reports on the consequences of various compounds “The basic combined oil has wound healing, such as Sesame, Kalamu, wild pistachio and walnut oils.

But “While combined formulations take advantage of the bioactive compounds of multiple oils, the specific contributions of individual components were not clear,” continues. “Hemp seed oils, as a single agent treatment, facilitates formulations and prevents potential interactions between bioactive compounds, but it still shows a strong therapeutic potential.”

New study It is added to an emerging body of scientific evidence to treat the potential of cannabinoids in order to treat wounds and deal with many other skin conditions.

Review published last year at Journal Pharmaceutics, for example, is found Cannabis oil offered “hopeful advantages” to help heal skin wounds Although the need to improve product formulas.

Researchers from Indian and Thai Universities, Cannabis Oils can see how “Ros-Reactive Oxygen Species (ROS) can reduce wounds when healing. These chemicals “is essential in development in development causing cells and tissue damage,” he explains

The authors of this study wrote cannabis oils “can help alleviate oxidant damage by promoting the mechanisms of Ros and antioxidants, to potentially improve wounds.”

“Cannabis oils, especially in its bioactive components, especially through the regulation of the skin wounds, through the regulation of the reactive oxygen species,” they wrote that the antioxidant properties of CBD increases Rose’s influences. “

Separate research published this year were found to be CBD as well Useful edition of some skin products as well as evidence of aging and antioxidant properties and wound healing.

“Generally, CBD has many features that can be used to develop cosmecimal products in cosmecimal products, such as sun protection products, and wounds to develop healing products.

In terms of wound healing, the discovery of the study “CBD has an impact on the expression of key genes involved in all phases of the wound healing process, protecting the potential for skin repair and anti-aging applications as a therapeutic agent.”

In the dermatology of clinical, cosmetical and researchers carried out in the journal, he found that Cannabidiol (CBD) and cannabigerol (CBG) Ointment “was effective in patients with eczema” to reduce efficiency and improve quality of life ““In some cases the symptom causes forgiveness.”

Transdermal ointment was used as an alternative to “regular therapy for” July 2022, “the results we wrote.” The results of the skin (water loss) were improved in sites studied (obstiments). “

Seeing a different research in the Dental Products CBDA, a CBD mouthwash and another botanical extraction can be a useful tool for promoting oral health Controlling the plate by controlling and reducing oral bleeding.

“The available evidence suggests that CBD is emphasizing the potential of anti-inflammatory, neurophodies, neurophodies, neurophatives, neuroprosters and antimicrobials,” the authors wrote.

Another paper published last year, published in the journal American Academy of Dermatology, found that Applying CBD-infused cream, ultraviolet (UV) is a lower risk of damage to ray exposure. Among those who used CBD cream, 21 percent had less damage than the control group, which received placebo. 47 percent of the other percent had compactive damage, and 11 percent show better results in front of the civet of the placebo’s cannabis.

Potential benefits are not limited to human applications.

A separate study published in the journal Limitary Science Limitations, which concluded that cannabis Treatment of dogs with plain surface diseases appear to be a “viable alternative”-Spezially if they have harmful side effects of some traditional steroid therapies

This study determined the effectiveness of the whole spectrum CBD oil in the autoimmune disease of a dog Lupus Eritematos (DLE). The condition that causes hair loss and redness can usually be treated with other corticosteroids and other drugs that can place a tension in the liver of a dog.

A veterinarian gave full spectrum oil with 2: 1 thc: CBD ratio, at once, a drop of day a day until three days and gradually increases until the optimal dose of symptoms. “

“In a few weeks, the dog has shown significant improvement in dermatological signals, accompanied by an improvement in the same period of the liver function,” the examination said. “It is interesting that the owner learned about an improvement of the dog’s behavior of the prednisolonus and receiving cannabis oil and within the first day.”

Photo courtesy Kimzy Nanney.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

(Tagstotranslate) highlighted

Continue Reading

Cannabis News

Tilray Medical announces commercial launch of medical cannabis in Panama

Published

on

By

Tilray Medical has announced the launch of its first medical cannabis product in Panama, part of the company’s continued global expansion and commitment to improving patient access to pharmaceutical grade cannabinoids worldwide.

Following the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP certified production facilities in Portugal through a joint venture with Solana Life Group S. de RL, the Product is to be distributed through Farmacias Arrocha, one of the leading pharmaceutical chains in Panama, where patients will be able to access Tilray Oral Solution CBD with medical prescription100. This is expected to provide patients and healthcare professionals with access to regulated medical cannabis of pharmaceutical quality through established healthcare channels.

Rajnish Ohri, International President, Tilray Brands, said: “At Tilray Medical, we believe that every patient deserves access to safe, consistent, pharmaceutical-grade cannabis products. The launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines around the world. We want pharmacists and patients to help shape the future of responsible access, advance medical education and provide high-quality treatment options that improve lives.”

The launch supports the Panamanian medical cannabis framework established by Law 242 of 2021 and follows important regulatory advances made by the Ministry of Health, including No. 0406 of May 12, 2026. The decision, which established the main conditions for the admission of patients. The Ministry also recently introduced the System for the Identification of Medical Cannabis Users and Authorized Caregivers (SIUCMAA), creating a structured way to authorize medical practitioners and register patients.

Manufactured in Portugal under strict European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use in patients with qualified medical conditions permitted under Panamanian law, where permitted. The products reflect Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety and regulatory compliance.

Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP certified medical cannabis products to regulated markets worldwide. The platform enables Tilray Medical to effectively support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations.

For more information:
Tilray
www.tilray.com

Continue Reading

Cannabis News

Medical Marijuana Is ‘Effective’ In Providing Relief To Patients With Restless Legs Syndrome, Study Shows

Published

on

By

People with restless leg syndrome (RLS) may find “significant” long-term relief with cannabis treatment, according to a new study.

While dopamine agonists have traditionally been the “first-line treatment” for RLS, recent studies indicate that gabapentinoids are now being recommended, the researchers said. Because cannabinoids, like gabapentinoids, inhibit a certain type of amino acid associated with the disorder, scientists decided to test their therapeutic effectiveness.

The open-label exploratory study, conducted by European researchers at the University of Madrid and published in the Journal of Neurology, found that a cannabis product containing 2.7 mg of THC and 2.5 mg of CBD was “effective in reducing RLS severity” among patients with multiple sclerosis and “associated idiopathic RLS.”

“Improvements were observed after 1 to 3 months of treatment and were maintained after 1 year among patients who continued therapy,” the study of 18 patients with RLS showed. For those who remained in treatment after a year, 67 percent “continued to show sustained improvement.”

The the findings it may not be surprising that cannabis in particular is known to reduce the severity of muscle spasms and related conditions, but its effectiveness for RLS is remarkable given that no state specifically lists it as a condition for medical cannabis.

Of course, RLS can be a symptom of other general disorders like multiple sclerosis, and some states give doctors more latitude to make recommendations for medical marijuana for any condition they see fit.

In any case, research outside of Spain could be based on research into alternative treatment options that could replace dopamine agonists in the treatment of restless legs syndrome.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Wyoming AG keeps cannabis on Schedule I, rejects federal reclassification

Published

on

By











Wyoming Attorney General Keith Kautz announced on July 7 that he would keep all marijuana products in Schedule I of Wyoming’s Controlled Substances Act, refusing to align the state’s cannabis policy with the federal reorganization order issued earlier this year.

Kautz, who also serves as Wyoming’s drug and substance abuse commissioner, held a public hearing on June 18 after filing an objection to aligning the state’s cannabis schedule with a federal amendment on May 27. State law requires the commissioner to give interested parties an opportunity to be heard after that objection, but only nine people responded. Four email comments supported leaving cannabis as a Schedule I drug, four as Schedule III. It was approved for use and one person attended the hearing to request that cannabis remain in Schedule I.

His decision follows an April 2026 order signed by U.S. Attorney General Todd Blanche that bans state-licensed medical cannabis, FDA-approved cannabis products, cannabis extracts and naturally derived delta-9 THC III.

Kautz’s office says: “After consideration of all stakeholder comments, the commissioner has determined that all marijuana products, including marijuana subject to the state’s medical marijuana license, will remain in Schedule I of the Wyoming Controlled Substances Act.”

His announcement adds, “The decision to reschedule medical marijuana and marijuana products is an important policy decision that is best left to the Wyoming Legislature and should not be made through administrative rule.”

Wyoming remains one of eight states without a medical cannabis program. A December 2020 poll by the University of Wyoming’s Wyoming Center for Polling and Analysis found that 85 percent of state residents support legalizing medical cannabis, despite a failed 2024 ballot initiative effort. Possession of three ounces or less carries up to 12 months in prison under current state law, and selling any amount is punishable by up to 10 years in prison and a $10,000 fine.

Kautz says his office will “properly schedule products approved by the United States Food and Drug Administration once that agency has approved the product,” pointing to the Schedules II and III listings of Cesamet and Dronabinol as evidence that the state complies with federal cannabinoid drug law.










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media